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Abstract 
MicroRNAs (miRNAs) involved in key signaling pathways and aggressive phenotypes of osteosarcoma (OS) was dis‑
cussed, including PI3K/AKT/MTOR, MTOR AND RAF‑1 signaling, tumor suppressor P53‑ linked miRNAs, NOTCH‑ related 
miRNAs, miRNA ‑15/16 cluster, apoptosis related miRNAs, invasion‑metastasis‑related miRNAs, and 14Q32‑associated 
miRNAs cluster. Herrin, we discussed insights into the targeted therapies including miRNAs (i.e., tumor‑suppressive 
miRNAs and oncomiRNAs). Using bioinformatics tools, the interaction network of all OS‑associated miRNAs and their 
targets was also depicted.
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Introduction
MicroRNA and cancer
MicroRNAs (miRNAs) are considered as a class of 
non-coding RNAs, which their expression patterns 
are demonstrated to be tissue and cancer-type specific 
[1]. MiRNAs are not only detectable in cells but also in 
various bio-fluids such as plasma and serum, as well as 
in follicular fluid, etc., namely extracellular miRNAs 
(ECmiRNAs) [2–4]. Circulating miRNAs from tumor 
cells have attracted the attention of researchers because 
of their diagnostic and prognostic potential, when are 
capable of preventing a novel opportunity for early pre-
diction of cancer and treatment. It is noteworthy that 
miRNAs are capable of regulating their target gene by 
either induction of miRNA degradation or abrogation of 
miRNA translation [5–7]. Aberrant expression levels of 
miRNAs have been found to be associated with the initia-
tion and progression of many kinds of cancers in tissues 
and cell lines, such as osteosarcoma (OS) [8, 9].
MiRNAs are capable of regulating 90% of protein-cod-
ing genes [10]. Mature miRNAs often play an important 
role in the pathogenesis of OS as an oncogenic or tumor 
suppressor agent because changes in miRNA regula-
tion seem to be markedly associated to cell proliferation, 
adhesion, invasion, migration and metastasis, as well as 
apoptosis [11, 12]. Consequently, these molecules may be 
regarded as good strategies for the development of prog-
nostic markers of various malignancies.
It is noteworthy that a given miRNA may have differ-
ent miRNA targets; on the other hand, it should be taken 
into account that multiple miRNAs are capable of regu-
lating a given miRNA target. Nevertheless, the interplay 
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between miRNAs and targeted genes is complex, when 
the intricate interplay is not obviously revealed [13].
The better in-depth understanding of the molecular 
mechanisms of miRNAs using pathway-based explora-
tory evaluations, mapping and characterization of 
miRNA can pave not only the way to characterize the 
pathogenesis of OS, but also provide miRNA-based ther-
apy for improving the prognosis of OS patients [2, 5, 7, 
13]. Furthermore, functional assessment of single miRNA 
can be great of importance to determine its role in the 
pathogenesis and tumorigenesis of OS [2, 7, 13]. There-
fore, miRNAs are undergoing clinical evaluation for 
many types of malignancies (Tables 1 and 2).
MiRNA-targeted therapies have been suggested to be a 
more promising approach to hamper aggressive biologi-
cal behavior of OS [14, 15]. Unlike multitude other kinds 
of cancer, there are no traditional markers found for OS. 
Therefore, the recognition of novel diagnostic miRNA 
biomarkers could finally have a prognosis or therapeu-
tic value in this disease [5]; however, metastatic nature 
of the disease and the histological response after adju-
vant chemotherapy is confirmed as the only predictor of 
event-free survival [5, 16]. As mentioned in Tables 1 and 
2, clinical trials are performed to provide novel predic-
tor and markers of response to therapy by evaluating the 
miRNAs expression patterns in the blood, body fluids, 
and tissue.
MicroRNA analysis
Most investigations have used methods such as quanti-
tative real time-PCR, gene arrays and miRNA sequenc-
ing for evaluating miRNA profiles at low cost with a high 
efficiency [17–19]. The conventional methods, including 
cloning, microarray, and in  situ hybridization are con-
sidered to be cost consuming techniques [20–23]. All 
pre-analytical and analytical approaches should be stand-
ardized for avoiding higher repercussions of technical 
biases on miRNA results, therefore, validation of results 
is needed before the translation of circulating miRNA 
patterns into a clinical evaluation [17, 24]. By develop-
ment of bioinformatics, different bioinformatics tools 
have been provided for managing miRNA biology data 
and investigating questions [25]
Annotation tools are applied to investigate miRNA 
biology. A platform for miRNA data should be taken into 
consideration in this regard. Many tools are developed 
in the field of annotation associated miRNA tools such 
as miRBase, Rfam, mirtronPred and MetaMirClust [25–
31]. For instance, miRBase is introduced as a searchable 
database (http://www.mirba se.org) that published 24,521 
miRNA loci from 206 species (e.g., 1872 miRNA precur-
sors of human, producing 2578 mature miRNAs) [26].
Structure tools are developed for the prediction and 
comparison of RNA structure [25, 32]. Structural fea-
tures of a given miRNA molecule can be elucidated by 
tools such as ViennaRNA software package [25, 32, 33].
Furthermore, identification tools are widely used based 
upon next-generation sequencing (NGS) information via 
Table 1 Clinical trial development by MiRNA; data were adapted from https ://clini caltr ials.gov
Study title Conditions Interventions Study type and phase
Plasma microRNA, lung cancer Lung cancer Screening Interventional study, not applicable
MicroRNA‑155 and telomerase 
reverse transcriptase, non‑muscle 
invasive bladder cancer
bladder cancer and disease Diagnostic method: miRNA ‑155
Diagnostic method: Human telom‑
erase reverse transcriptase
interventional, not applicable




Other: blood sample Interventional study, not applicable
Circulating miRNAs, breast cancer Breast cancer Drug: tamoxifen, letrozole, anastro‑
zole, exemestane
Interventional study, Phase 4
A 6 microRNA Tool for Stratifying 
Stage II colon cancer
Colonic
Chemotherapy
A 6 microRNA stratified tool Interventional study, Not applicable
MicroRNA in NAF, serum, and tissue, 
breast cancer
Breast Cancer
Ductal carcinoma in situ
Drug application: intranasal oxytocin Interventional study, Phase 2
A multicenter phase I study of 





Drug application: MRX34 Interventional study, Phase 1
MicroRNA involved in cutaneous 
squamous cell carcinoma
Cancer of the Skin Genetic: arm A Interventional study, not applicable
Plasma miRNAs for Predicting Radio‑
sensitivity in Advanced Non‑small 
Cell Lung Cancer
Advanced non‑small cell lung 
cancer
Radiotherapy Interventional study, not applicable
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various algorithms and tools such as miRDeep (miRD-
eep/miRDeep2) and miRanalyzer [25, 34, 35] by which 
miRNA characteristics such as sequence conservation, 
structural properties (i.e., hairpin and minimum free 
energy) can be obtained.Moreover, miRNAFold as a fast 
ab  initio method is used for predicting miRNA in the 
genome [36, 37]. Computational algorithms have pro-
vided harmonize experimental strategies for discover-
ing and validating novel miRNAs [23, 37]. Furthermore, 
network analysis is taken into consideration for provid-
ing drug target, as well as for planning novel therapeutic 
and diagnostic approaches. Network biology is developed 
to inspect components for deducing valuable data from 
large transcriptomic datasets, by which metabolic net-
works depend on each other are capable of showing the 
behavior of the network biology [38–40].
Circulating MicroRNAs as key regulator in OS pathobiology
Different clinical studies in the last several years have 
demonstrated that miRNAs, especially circulating miR-
NAs in serum are involved in OS development and pro-
gression. Therefore, they can potentially be applied as 
diagnostic and prognostic markers [41].
Mature miRNAs are first detectable in serum and 
plasma, and can thereafter be detected in biological flu-
ids [42–45]. It has been suggested that circulating miR-
NAs are more likely to undergo selective packaging and 
release, and their secretion in cells could be linked to a 
given pathological condition [43, 45, 46],
Ample evidence indicates that the uptake of circulat-
ing miRNAs by their target cells is absolutely essential 
for eliciting their regulatory functions [45, 47]. Pathways 
involved in the uptake of circulating miRNAs are pre-
sented in Fig. 1.
Overall, increasing evidence reveals that the release of 
ECmiRNAs in the extracellular harsh environment can 
Table 2 Observational clinical trial development by  MiRNAs; all data was  adapted and  collected from  https ://clini caltr 
ials.gov
Study title (reference) Conditions Interventions Type
Circulating microRNA for cardiotoxicity in breast cancer Breast cancer – Observational
MicroRNAs Tool for stratifying stage II colon cancer Colon cancer, effects of chemotherapy Device: miRNA tool Observational
MicroRNA processing enzymes dicer and drosha Skin cancer – Observational
MicroRNA blood test for lung cancer screening Lung cancer – Observational
Micro RNAs for prediction of response to androgen depriva‑
tion therapy




Investigating the role of novel molecular profiles, micro‑
RNA’s, and their targets in colorectal cancer progression
Colorectal cancer Biomarker study Observational
MIRNA profiling of breast cancer Breast cancer – Observational
Circulating microRNA as a tool for primary brain tumors Brain tumors – Observational
The utility of circulating tumour cells and plasma microRNA Esophageal cancer Blood draw Observational
Anti‑IMP3 Autoantibody and MicroRNA signature blood 
tests for detection of metastatic kidney cancer







MicroRNAs for diagnosis of pulmonary cancer Pulmonary cancer Blood punction Observational
Circulating miRNAs. ICORG 10–11, V2 Breast ccancer, Recurrent breast cancer – Observational
Lipidomics, proteomics, micro RNAs and volatile organic 
compounds
Pancreatic neoplasms blood and bile Observational
Chemoresistance in epithelial ovarian cancer Ovarian Cancer – Observational
MicroRNA‑10b in patients with gliomas Astrocytoma, oligodendroglioma, oligoastrocytoma – Observational
MicroRNAs in neurofibromatosis type 1 Glioma
Neurofibromatosis Type 1
– Observational
Microarray analysis in basal cell carcinoma Basal cell carcinoma – Observational
Microarray analysis of microRNA in cutaneous squamous 
cell carcinoma
Cutaneous squamous cell carcinoma – Observational
MicroRNA expression in renal cell carcinoma Renal cell carcinoma – Observational
The role of microRNA in cutaneous melanoma Melanoma – Observational
Page 4 of 20Otoukesh et al. Cancer Cell Int          (2020) 20:254 
be mediated for intercellular connection by microvesi-
cles, exosomes, apoptotic bodies, and high density lipo-
protein (HDL), as well as argonaute (AGO) protein 
complex [47]. Therefore, the release of circulating miR-
NAs from cancer cells play a substantial role in tumori-
genesis of recipient cells (normal cells). It is noteworthy 
that further clarification of these pathways will require an 
in-depth understanding of the mechanisms that under-
lie release of cellular miRNAs, regulation and uptake of 
circulating miRNAs in order to elucidate cancer biology. 
An increasing body of evidence suggested that ECmiR-
NAs can be involved in the pathophysiological condition 
of cancer. Therefore, these ECmiRNAs may be delivered 
to the recipient cells through many pathways, by which 
they are capable of regulating translation of their target 
genes. The evaluation of single ECmiRNAs (e.g., exoso-
mal miRNAs or protein-bound miRNAs) may be useful 
in comparison with total ECmiRNAs. As a matter of fact, 
ECmiRNA investigations need technological advance-
ment with standardized protocols for obtaining reliable 
findings in terms of disease biology, where may result in 
the development of new therapeutic strategies [47].
Microvesicles may be secreted by many cell types 
including many types of cancerous cells, B cells, endothe-
lial cells, dendritic cells and neurons [48–50]. Circulating 
miRNAs are considered as noninvasive biomarkers, 
where a variety of strategies are being conducted in clini-
cal studies for determining values of circulating miRNAs. 
Circulating miRNAs have been introduced as a potential 
marker for early diagnosis and monitoring of OS. There-
fore, validation of these markers in clinical trials is cur-
rently needed. Most investigations have used methods 
for evaluating circulating miRNAs such as quantitative 
real time-PCR, gene arrays and sequencing [51]. Circu-
lating miRNAs are summarized in Table  3 for monitor-
ing of OS, where a list of miRNAs are provided based on 
their oncogenic and tumor suppressor activity consisting 
of clinicopathologica status.
Other miRNAs that are correlated with the OS devel-
opment include the following: miR-20a-5p, miR-106a-5p, 
miR139-5p, miR451a, miR16-5p, miR-25-3p, and miR-
425-5p demonstrated to be weakly expressed in the 
serum of patients suffering from OS in comparison with 
healthy controls. Aforementioned miRNAs have been 
suggested to serve as diagnostic markers for differentiat-
ing healthy cohort and OS [52].
The decreased expression level of circulating miR-125b 
has been indicated to be linked to poor disease-free sur-
vival in patients suffering from OS, and this miRNA was 
capable of predicting the cisplatin resistance in patients 
with OS, where decreased miR-125b was related to high 
tumor stages [53]. Decreased level of miR-125b as a 
tumor suppressor has been found in human OS tissues 
[54, 55], and its weak level was found to be related to 
higher TNM stage, large tumor size, and metastasis [56, 
57].
Plasma miR-34b was introduced as a new potential 
therapeutic marker for OS, where its expression was 
causally linked to metastasis, thus leading to develop-
ment of OS [58]. A three-miRNA signature including 
down-regulation of plasma levels of both miR-199a-3p 
and miR-143 and up-regulation of plasma miR-21 level 
has been demonstrated in patients with OS, which were 
able to discriminate OS from controls subjects [59]. Yuan 
et  al., reported that higher Enneking stage and chemo-
therapeutic resistance can be markedly associated with 
serum miR-21 level, where its serum level can serve as an 
unfavorable prognostic factor for OS [60].
Lower serum and tissue miR-598 levels have been 
revealed to be associated with migration, invasion and 
proliferation of OS cells. A growing body of evidence 
demonstrates that miR-598 is involved in OS progres-
sion by targeting platelet-derived growth factor (PDGF) 
-β and mesenchymal epithelial transition (MET), as well 
as modulation of osteoblast differentiation in the micro-
environment, indicating its potential as diagnostic, prog-
nostic, and therapeutic marker [61].
MiRNA may be 
enwrapped with 
microvesicles or 
aached directly to 
cell membranes. 
Specific cell surface 
receptors  play their 
role by taken 
up RNA- proteins 
involved in miRNA 
biogenesis 
MiRNA may deliver 
to the recipient cells 
by permission of 
specific receptors on 
cell membranes of 
recipient cells, or by 
recognion 
molecules on vesicle 
MiRNA 
transfer via cell gap 
juncon, released to 
extracellular 
environment 
Fig. 1 Possible ways to release circulating miRNAs; 3 pathways 
including extracellular vesicles, RNA‑binding proteins and/or transfer 
through cell gap junction are involved. In addition, the topology 
of the network was analyzed based on degree metrics in order to 
find the most important nodes. According to the findings, 5 nodes 
with large degrees in our large network (i.e., > 9, see green nodes) 
including BCL2, VEGFA, CCND1, PTEN and MET were identified as 
potential hub nodes, (Additional file 1, and Fig. 2)
Page 5 of 20Otoukesh et al. Cancer Cell Int          (2020) 20:254  





miR‑9Om Increased levels of miR‑9 were found to be related to higher TNM stage, distant metastasis and large tumour size; as well as poor 
S
Fei et al. [233]
miR‑17Om Increased level was detected in OS patients, where it was linked to poor S; Serum miR‑17 levels was reported to be linked to 
tensin homolog (PTEN) expression and tissue phosphatase
Li et al. [234]
miR‑24Om Increased serum and tissue miR‑24 levels were detected in OS patients Sun et al. [235]
miR‑27aOm Higher miR‑27a levels was detected to be linked to higher clinical stage, and distant metastasis; Higher miR‑27a levels was 
found to be correlated with poor response to chemotherapy, and was capable of differentiating OS from HC; it serves as an 
independent prognostic marker of unfavourable survival
Tang et al. [236]
miR‑34bT Decreased plasma level and low tissue expression of miR‑34b were detected, lower level has been found in metastatic patients, it 
was considered as circulating tumour suppressor miRNA
Tian et al. [58]
miR‑25‑3pOm miR‑25‑3p level was increased in OS patients; its increase was linked to poor PFS, and it was capable of differentiating OS from 
healthy control.
Fujiwara et al. [63]
miR‑29  familyOm Higher miR‑29a/b/c levels were detected to be associated with OS in evaluated patients; this markers serves as independent 
prognostic factors of unfavourable survival




MiR‑21 levels increased in OS, whereas miR‑143 and miR‑199a‑3p levels were decreased in OS
Decreased levels of MiR‑21 and miR‑143 were found to be linked to metastasis and histological subtype; Low level of miR‑199‑3p 
was linked to histological subtype
Increased miR‑21 was found in the blood, where its high expression was linked to higher Enneking stage and chemotherapeutic 
resistance
Ouyang et al. [59]; 
Yuan et al. [60]
miR‑95‑3pTs Decreased serum level of miR‑95‑3p was indicated to be linked to clinical stage, metastasis and chemotherapy response. It was 
considered as circulating tumour suppressor miRNA
Niu et al. [238]
miR‑125bOm Decreased level of miR‑125b was linked to advanced tumour stages
Furthermore, it was capable of differentiating chemotherapy‑resistant patients from chemotherapy‑sensitive
Luo et al. [53]
miR‑133b
miR‑206Ts
MiR‑133b and miR‑206 downregulation were found to be related to advanced tumour grade, metastasis and recurrence in 
OS patients’ sera, as well as poor response to chemotherapy in patients. Decreased levels of both miRNAs is attributed to 
18 months’ survival time, which is indicated to be a shorter survival in comparison with the mean 24 months survival time in 
patients with decreased level of only one miRNA; miR‑133b and miR‑206 may present opportunity as non‑invasive biomarker 
for diagnosis and prognosis of OS
Zhang et al. [239]
miR‑148aOm Increased expression of circulating miR‑148a was linked to increased tumour size and distant metastasis and a negative association 
with five‑year survival in OS patients, where it was revealed to be an independent prognostic factor of unfavourable survival;
As a matter of fact, 148a has been suggested to be a vindicator marker for
progressive phenotype, and a novel diagnostic biomarker
in the peripheral blood for determining poor prognosis in patients suffering from
OS
Ma et al. [240]
miR‑152Ts Lower serum and tissue levels of miR‑152 levels were linked to
Enneking and metastasis in OS patients; decreased level revealed to be capable of differentiating OS from HC, and serves as an 
independent prognostic factor for unfavourable survival
Wang et al. [241]
miR‑196a,
miR‑196bOm
Increased levels of tissue and serum miR‑196a and miR‑196b were detected;
Higher serum miR‑196a and miR‑196b and their co‑expressions were linked to advanced tumour grade, recurrence and metasta‑
sis status in OS patients; expression levels of both MiRs were related to unfavourable survival




MiRs levels were elevated in OS patients and their downregulation were found in
postoperative samples; MiR‑195‑5p and miR‑199a‑3p were found to be linked to metastasis status, whereas miR‑199a‑3p and 
miR‑320a levels were related to histological subtype
Lian et al. [62]
miR‑199a‑5pOm Increased levels of miR‑199a‑5p levels were detected in OS patients; its decreased level were found in postoperative samples; 
MiR‑199‑5p was capable of differentiating OS from healthy control
Zhou et al. [243]
miR‑221Om Increased level of miR‑221 in OS patients, and its tissue and serum levels was found to be prognostic factor of unfavourable 
survival; MiR‑221 was found to be capable of differentiating OS from HC
Yang et al. [244]
miR‑223Ts Decreased level of miR‑223 was linked to advanced clinical stage and distant metastasis Dong et al. [245]
miR‑300Om Increased tissue and serum miR‑300 levels were detected in OS patients; higher clinical stage and distant metastasis were found 
to be linked to increased level of miR‑300 levels; serum levels found to be reduced in OS patients after curative surgery; serum 
miR‑300 was suggested as an independent prognostic marker of unfavourable survival
Liu et al. [246]
miR‑326Ts Lower serum and tissue levels of miR‑326 levels were detected in OS patients; it serves as circulating tumour suppressor miRNA; 
MiR‑326 was capable of differentiating OS from HC;
Decreased serum miR‑326 levels were linked to higher clinical stage and distant metastasis, whereas its decrease tissue level was 
related to distant metastasis; its lower serum level was suggested to be an independent prognostic factor of unfavourable 
survival
Cao et al. [247]
miR‑497Ts A circulating tumour suppressor miRNA; lower miR‑497 levels was found to be liked to response to chemotherapy, and clinical 
stage, distant metastasis
Pang et al. [248]
Ts tumour suppressor miRNA(s), Om oncomiRNAs
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Up-regulation of four plasma miRNAs (miR-320a, 
miR-374a-5p, miR-195-5p, and miR-199a-3p,) have been 
previously identified in OS patients, of which plasma lev-
els of miR-195-5p and miR-199a-3p have been found to 
be linked to the metastatic OS, whereas miR-199a-3p and 
miR-320a plasma expression levels were revealed to be 
related to histological subtype. Moreover, these miRNAs 
were capable of discriminating OS patients from healthy 
subjects. Postoperative up-regulation of these plasma 
miRNAs was also detected [62].
Circulating miR-25-3p level has been found to be 
increased in OS in the validation cohort. In addition, 
serum miR-25-3p levels were revealed to be a predictor 
of patient prognosis as a blood-based biomarker, where 
its association with tumor burden has been revealed in 
both invivo experiment and patients [63]. Emerging evi-
dence suggests that down-regulated serum miR-101 
level can be markedly linked to higher clinical stage and 
distant metastasis, as well as poor overall survival and 
recurrence free survival, suggesting its potential for OS 
diagnosis, with a favorable specificity/sensitivity [64].
Another study indicated that low serum miR-375 level 
could be linked to high clinical stages, increased tumor 
size, and distant metastasis, as well as chemoresistance 
after surgery in OS. Furthermore, the miR-375 expression 
may be a novel target for diagnosis, prognosis, and chem-
osensitivity prediction in OS patients [65]. It is notewor-
thy that efforts are at the beginning of assessing miRNAs 
expression patterns in OS initiation and progression.
PI3K/AKT/MTOR pathway ‑related miRNAs and MAPK 
pathways‑related MicroRNAs
The tumor suppressor phosphatase and tensin homolog 
(PTEN) (200  kb gene on hromosome10q23) suffers loss 
of function in many types of malignancies such as bone 
metastases, and OS, which is described to act as negative 
regulator of the PI3K/Akt activation [66], which may be 
influenced by genetic mutation, loss of heterozygosity 
(LOH) of chromosomal regions, DNA promoter hyper-
methylation, and miRNAs-mediated gene expression [5, 
67]. PTEN is a multifunctional tumor suppressor that is 
negatively involved in the regulation of the Akt pathway 
for preventing cell proliferation [5]. PTEN mRNA level 
has been previously found to be inversely linked to up-
regulation of oncogenic miR-92a, miR-17, miR-130/301 
families and miR-26 families. PTEN is involved in antag-
onizing signaling via the PI3K/PTEN/Akt pathway, which 
was demonstrated to play a substantial role in progres-
sion and development of OS through inducing cell prolif-
eration and inhibiting apoptosis [68].
PTEN as a target of miR-26a, miR-106b-25 cluster 
(7q22.1) and miR-17-92 cluster family (13q31.2) have 
been confirmed to be decreased in OS [68–71], where 
plays a key role in the development of OS by inducing 
cell proliferation and suppressing apoptosis. In the litera-
ture, miR-17-92 cluster, miR-106b-25 paralog cluster and 
miR-106a-92 clusters have been verified to be increased 
in OS cell lines and different cancers [68, 72, 73]. Accu-
mulating evidence indicates up-regulation of miR-17-92 
in OS, as well as up-regulation of miR-106a (miR-106a-92 
cluster) and miR-106b (miR-106b-25 clusters) [74, 75].
MiR-17 was up-regulated in OS tissues by which PTEN 
could be inhibited via binding to its 3′-UTR, indicating 
that miR-17 as oncogene has an important role in OS cell 
growth, migration, and invasion [76].
Increasing evidence suggests that miR-221 plays a sub-
stantial role in cancer development. MiR-221 was capable 
of promoting OS  cell  proliferation, invasion and migra-
tion at least partly via  reducing PTEN [77]. Up-regula-
tion of miR-221 was identified to be capable of inducing 
cisplatin resistance and cell survival in both human OS 
cell (SOSP-9607) and MG63 partly via PI3K/PTEN/Akt 
pathway through targeting PTEN pathway, while knock-
down of miR-221 has been revealed to be involved in cell 
growth inhibition, the increase of cisplatin resistance and 
induction of cell apoptosis [78], showing its potential as a 
therapeutic strategy for the prevention of OS.
A study suggested that over-expression of miRNA-21 
as an oncogene could be able to activate the PTEN/PI3K/
AKT signaling via down-regulating the expression level 
of PTEN in MG-63 as OS cell line, where its expression 
level was found to be positively linked to the expression 
of AKT/p-AKT, suggesting that miR-21 is implicated in 
regulation of the cell proliferation and invasion as shown 
previously on MG-63 cells [79]. PTEN has been sug-
gested as a target of miR-21, which is capable of activat-
ing PI3K/Akt pathway via inhibiting PTEN expression 
level [80].
Abnormal expression of mitogen-activated protein 
kinase 7 (MAPK7) has been defined as a biomarker for 
tumor development in high-grade OS [81, 82]. MiR-
143 has been evaluated as a tumor suppressor in many 
kinds of malignancies [83–85]. Down-regulation of miR-
143 was found in OS tissues and cells, whereas over-
expression of miR-143 can play a role in inhibiting the 
proliferation, migration and invasion of OS cells. Fur-
thermore, the miRNA level of MAPK7 was reported to 
be negatively linked to miR-143 expression in OS tissues. 
Thus, MAPK7 could be a target of miR-143, and forced 
expressed miR-143 has been revealed to be implicated in 
decreasing the MAPK7 protein expression [86].
It has been revealed that miR-143 was able to suppress 
epidermal growth factor receptor (EGFR) via its down-
stream ERK/MAPK signaling cascades for negative regu-
lation of Matrix metallopeptidase 9 (MMP-9) level in OS 
cell lines; therefore, miR-143, EGFR, and MMP9 have 
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been suggested as key targets for preventing OS invasion 
[87]. Competitive endogenous RNAs (ceRNAs) regula-
tory network indicated that LINC00323, LINC00028, 
SNHG1 (lncRNAs), hsa-miR-7, and hsa-miR-124 are 
importantly implicated a new mechanism of interaction 
between some mRNAs (i.e., RAP1B, ATF2 and PPM1B) 
involved in the MAPK pathway [88].
Over-expression of hsa-miR-124 and hsa-miR-7 dem-
onstrated to have favorable prognosis value. Decreased 
miR-7 level in OS has been found to be linked to poor 
prognosis [89]. In addition, miR-124 expression level has 
been revealed to be markedly lower in the metastatic OS 
as compared to non-metastatic OS. MiR-124 serves as a 
tumor suppressor by inhibiting expression of Rac family 
small GTPase 1 [88, 90].
MTOR and RAF‑1 Signaling MiRNAs in OS
A study demonstrated that miR-24 was decreased in OS, 
leading to up-regulation of lysophosphatidic acid acyl-
transferase β (LPAATβ) and induction of OS cell prolif-
eration. LPAATβ has been defined to be implicated in the 
regulation of OS cell proliferation, partly through mTOR 
and Raf-1 signaling pathways [91]. Nevertheless, fur-
ther clarification will need the systematic evaluation of 
the molecular mechanisms involved in the regulation of 
LPAATβ in OS.
MiR-199a-3p (1q24.3) has been suggested to be impli-
cated in suppression of mTOR signaling via binding of 
the 3′UTR of mTOR. Restored miR-199a-3p expression 
was able to decrease mTOR and p-mTOR and enhance 
cell populations via increasing  G1-phase population, 
leading to suppression of cellular growth, proliferation in 
OS cells. In another word, increased level of miR-199a-3p 
via transfection has been indicated to be capable of both 
decreasing OS cell growth and migration by enhancing 
 G1-phase population, decreasing the S-phase, and restor-
ing miR-199a-3p level [92].
Up-regulated miR-101 was capable of enhancing 
mTOR expression at both mRNA and protein expres-
sion level in OS, resulting in suppression of cell prolifera-
tion and promotion of apoptosis in an mTOR-dependent 
manner [93].
MTOR/p70S6K signal transduction pathway has been 
revealed to be associated with positive surgical stage and 
metastasis status, indicating the prognostic value of this 
pathway in OS patients [94].
Functional studies demonstrated that miR-99a is a 
key regulator of mTOR [95–97]. It has been revealed 
that miR-99a was negatively linked to mTOR mRNA 
in OS, where low miR-99a expression and high mTOR 
expressions were markedly linked to high surgical stage, 
and metastasis recurrence, therefore, miR-99a-high/
mTOR-low patients showed relatively better outcomes, 
indicating that miR-99a-low/mTOR-high co-expression 
can potentially be served as a novel prognostic marker 
for OS [97].
MicroRNA‑15/16 cluster in OS
The miR-15/16 cluster has been considered to be 
involved in the suppression of tumor in many kinds of 
malignancies. This cluster has been indicated to target 
BCL2, WNT3A, RAB23 genes and other genes impli-
cated in the G1/S transition, e.g., cyclin D1, cyclin D3, 
cyclin E1, and CDK6 [5, 98].
MiR-16 was demonstrated to be weakly decreased in 
OS, while its over-expression has been observed to be 
capable of suppressing IGF1R/Kras/Raf1/MEK/ERK 
pathway, leading to suppression of cell growth in OS, 
indicating that exogenous up-regulation of miR-16 may 
provide a therapeutic strategy in the near future [99]. In 
addition, restoration of miR-16 in OS cells has been indi-
cated to be attributed to inhibition of proliferation via 
suppressing IGF-1R and the Ras/Raf/MAPK pathway, 
while MAPK activation was capable of inducing prolif-
eration and anti-apoptotic pathways in OS cells [5, 100].
MiR-16-1-3p and miR-16-2-3p together with miR-
16-5p were demonstrated to be down-regulated in 
OS and mouse model with engineered WWOX gene 
[101–104], while tumor suppressive effects of 16-1-3p 
and miR-16-2-3p were markedly higher in OS than that 
of miR-16-5p strand [105]. On the other hand, obliga-
tory knock-outs of neither miR-16-1 nor miR-16-2 could 
contribute to OS in mice model [106, 107]. These find-
ings need rigorous analysis in the light of some inter-
pretation including additional oncogenic events for 
development OS in mice or involvement of reduction of 
these miRNAs in later stages of tumorigenesis in mice or 
implication of both events, and/or the possibility of dif-
ferences mechanisms for both mice and humans [105]. 
High expression levels of miR-16-1-3p and miR-16-2-3p 
together with miR-16-5p have been found to be associ-
ated with a decrease in Akt Ser473 phosphorylation that 
is compatible with over-expression of PI3K/Akt path-
way in osteoblasts with FGFR2 up-regulation [105, 108]. 
These miRNAs exhibited anti-survival and pro-apoptotic 
activities, as well as anti-invasive and chemoresistance-
lowering effects in human OS cells at endogenous expres-
sion.These mimics have been suggested as key targets for 
improving the outcomes of chemotherapy in OS [105].
P53‑linked miRNAs in OS
Based on the data presented in the literature, aberrant 
expressions of miR-34a, miR-34b and miR-34c have 
been markedly linked to p53 status, indicating the pos-
sibility of the regulation of the Mir-34 gene by p53. 
The inactivating mutations of p53 have been revealed 
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to be often associated with the reduction of miR-34a in 
tumors [109, 110].
MiR-34a, a member of miR-34  s family, is a tran-
scriptional target of p53 tumor suppressor, which is 
capable of suppressing cell proliferation and metas-
tasis in OS by reducing the cMet gene [111]. miR-34a 
plays a substantial role in inhibiting tumorigenesis via 
down-regulation of its targets, e.g., Cyclin D1, E2F3, 
E2F5, CDK4, CDK6, N-myc, c-Met and Bcl-2 [112–
114]. On the other hand, the p53 network has been 
indicated to be able to inhibit tumorigenesis via activa-
tion of its transcriptional targets. MiR-34 may play a 
key role in suppressing inappropriate cell proliferation 
and over-expression of miR-34a is capable of decreas-
ing c-Met protein and miRNA, resulting in inhibition 
of the tumor growth and metastasis in OS although 
other putative miR-34a target genes may be potentially 
involved in the progression of OS. Taken together, the 
absence of miR-34a has been found to attribute to the 
development of a variety of malignancies [115, 116].
MiR-34a has been reported to be capable of regulat-
ing genes involving in DNA damage and repair. MiR-
34a was found to decrease in OS, and its expression 
has been suggested to be associated with the expres-
sion of its target genes (i.e., CDK6, E2F3, Cyclin E2,and 
Bcl-2) partly in a p53-dependent manner, and subse-
quently resulted in the miR-34  s-induced cell cycle 
arrest, and apoptosis [117]. On the other hand, it has 
been indicated that miR-34a is implicated in sup-
pression of OS growth by reduction of Eag1 expres-
sion [118]. The p53-dependent miR-34c decreased 
runt-related transcription factor 2 (RUNX2) in OS, 
and Nutlin-3-mediated stabilization of p53 was found 
to be capable of promoting miR-34c level and reduc-
ing RUNX2, resulting in inhibition of U2OS cell pro-
liferation [119]. MiR-34a and miR-199a-3p have been 
demonstrated to have important roles in blocking cell 
growth and elevating cell apoptosis via p53 signaling 
pathway by down-regulating its targets (mTOR, MET 
and MDM4 [an inhibitory factor of TP53] in OS [120]. 
An investigation reported that p53-associated miR-34a 
and miR-192 expression levels can be served as a prog-
nostic marker for risk stratification in OS [121].
MiR-215 has been found to be linked to cell cycle 
control, cell proliferation [122], and play a key role in 
p53-mediated chemoresistance, where miR-215 over-
expression has been found to be attributed to resist-
ance to methotrexate (MTX) and tomudex (TDX) in 
OS cell lines [123]. A growing body of evidence sug-
gests that miR-34a, miR-192, and miR-215 can be con-
sidered as prognostic markers candidate in OS.
Notch signaling‑related micro RNAs
Increasing evidence indicates that miR-199b-5p expres-
sion was markedly increased in OS tissues, when 
compared with normal tissues. Furthermore, the miR-
199b-5p inhibitor was found to be capable of altering 
expression levels of Notch pathway components includ-
ing JAG1, Notch1, HES1, Dll1, Dtx1 via regulation of 
HES1 and Dtx1 expression levels [124]. As demonstrated 
previously, the balance between HES1 and Dtx1 is impli-
cated in regulating Notch signaling [124, 125]; therefore, 
miR-199b-5p play a key role in the regulation of Notch 
signaling in OS.
A study indicated that over-expression of miR-199b-5p 
was linked to adverse outcomes including high tumor 
grade, metastasis, recurrence, and shorter overall sur-
vival in patients suffering from OS [126]. Notch signal-
ing is involved in the development of many kinds of cells 
and tissues (e.g., bone development) via affecting stem 
cell renewal, proliferation, differentiation, etc. As a mat-
ter of fact, this pathway plays a key role in keeping the 
balance between proliferation and differentiation and its 
changes (i.e., increased expression of Notch ligand and 
receptors) can lead to the development of cancers such as 
OS [127–130].
Accumulating evidence indicates tumor suppressor 
miR-34a is capable of regulating p53 and Notch signal-
ing in OS [131, 132]. Notch signaling components have 
been demonstrated to be increased in primary OS [133], 
and the miR-34 reduction was revealed to be associated 
with the genetic and epigenetic changes of miR-34 genes 
in primary OS [117, 134].
Furthermore, miR-34a and miR-200b were found to 
play a crucial role in the regulation of a number of genes 
including Notch-1, VEGF, MMP-2 and MMP-9 in OS 
cells. Diallyl trisulfide (DATS), an organic trisulfide 
derived from Allium vegetables, is capable of suppress-
ing development and aggressiveness of OS through 
down-regulating its downstream genes (MMP-2, MMP-9 
Hes-1, and VEGF) and increasing a panel of tumor-sup-
pressive microRNAs, e.g., miR-34a, miR-200b/c, miR-
143, and miR-145, which are usually lost in OS; thus they 
are considered as new targets for developing therapeutic 
strategies [135].
In addition, re-expression of both miR-34a and miR-
200b via transfection were related to down-regulation 
of Notch-1 expression, resulting in suppression of cell 
proliferation, invasion and angiogenesis in OS. Addi-
tionally, miR-200b and miR-200c have been reported to 
be decresed in OS cells, and Notch-1 inactivation was 
found to be implicated in up-regulation of miR-200b and 
miR-200c. Additionally, DATS was capable of inducing 
re-expression of miR-200b and miR-200c, indicating a 
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valuable component for reverting aggressiveness of dis-
ease [135].
MiR-34c is implicated in suppressing osteoblast dif-
ferentiation and enhancing osteoclastogenesis partially 
by inhibiting Notch signaling components e.g., Notch1, 
Notch2, and Jag1 in mice. Further development is needed 
in-depth understanding of miR-34 and Notch pathway 
interactions that underlie their regulation to provide 
therapeutic strategies modulating miR-34 signaling [134].
MiRNAs involved in apoptosis
Apoptosis is considered as a homeostatic mechanism 
which can be triggered by two major apoptotic path-
ways including mitochondria-mediated intrinsic path-
way and death receptor-mediated pathway (extrinsic 
apoptotic pathways), by which is capable of activating a 
group of cysteine proteases including caspase-9 and- 8, 
respectively. These caspases play an important role in the 
activation of caspase-3, -6, and -7, which are capable of 
promoting cleavage of different cellular proteins in order 
to induce cell death [136, 137].
MiRNAs are not only responsible for regulation of the 
apoptotic extrinsic apoptotic pathways via different key 
junctions such as TRAIL-R, Fas ligand (FasL), TWEAK 
and IP3R, BIRC5, and CASP7, but also play an important 
role in the regulation of intrinsic pathway via junctions 
such as cathepsin and Bcl-2 family members and inflam-
mation through IL3RB and PI3K [137].
Intrinsic apoptotic pathway involved MiRNAs in OS
Down-regulation of miR-133a was found in primary 
OS to be linked to tumor progression and prognosis of 
disease [138]. It should be taken into consideration that 
molecular mechanisms by which miR-133a play its role 
in cell proliferation, and invasion in OS will need further 
development. A study indicated miR-133a is involved 
in inhibition of progression and metastasis via target-
ing insulin-like growth factor 1 receptor (IGF-1R) in OS 
and indirectly suppresses the AKT/ERK signaling path-
ways [139]. IGF-1R is participated in regulation of cell 
proliferation, and apoptosis [140]. Therefore, miR-133a 
might be a target and effective biomarker for metastasis 
and prognosis of OS. MiR-133b expression level has been 
recorded to be decreased in OS, and its over-expression 
was found to reduce BCL2L2, MCL-1, IGF1R, MET and 
FAK and inhibit Akt activation, resulting in inhibition 
of cells proliferation, migration, and invasion, thus lead-
ing to the promotion of apoptosis in OS cells [141]. Both 
BCL2L2 and MCL-1 are defined to be as members of the 
Bcl-2 family, which are capable of increasing cells sur-
vival and therefore exhibit anti-apoptotic activity via the 
mitochondrial signaling pathway [142, 143].
It has been indicated that loss of the miRNA29a level 
may be involved in up-regulation of BCL2 and MCL1, 
leading to resistance of cells to apoptosis, and progres-
sion of OS, while over-expression of miRNA29a was 
associated with increased E2F1 and E2F3 expression 
levels as a tumor suppressor and loss of both BCL2 and 
MCL1 expression levels [144]. The E2F is a panel of genes 
that have a key role in the regulation of the cell cycle and 
DNA synthesis in mammalian cells [145].It has been 
revealed that knockdown of miR-29 result in suppres-
sion of cell proliferation and induction of apoptosis in OS 
by inducing PUMA through inhibition of TGF-β1 levels, 
suggesting miR-29 anti-tumor activities [146].
Extrinsic apoptotic pathway involved miRNAs in OS
Over-expression of miRNA cluster 17-92 and its two par-
alogs (i.e., 106a-363 and 106b-25) are indicated to be an 
oncogenic event in OS cell lines. Accumulating evidence 
suggests that expression of miR-17, miR-18a, miR-92a, 
and miR-106b have been contributed to FAS repression 
[147].
Furthermore, over-expression of the miR-17-92 clus-
ter, particularly miR-20a level was demonstrated to be 
involved in FAS suppression in OS cell lines that contrib-
utes to tumor cell survival and metastasis (lung metas-
tases) in OS cells [148]. The involvement of Fas-FasL 
signaling in tumor progression and suppression can be 
controversially different in many kinds of tumors. It not 
only plays an important role in apoptosis as a signal, but 
also in some examples stimulates cell proliferation via 
nonapoptotic signaling [147, 149, 150].
Suppression of BIM as a pro-apoptotic gene was 
induced by the miR-17-92 cluster in many types of 
tumors, and osteoblasts [151]. However, only the miR-
17 expression level has been found to contribute to 
decreased pro-apoptotic BH3-only gene (BIM) expres-
sion in OS [147]. Current evidence suggests a superordi-
nate role of the miR-17-92 cluster in OS biology, where 
several pathways and mechanisms may be involved in the 
development of OS [147, 152].
Invasion‑metastasis‑related microRNAs in OS
As indicated, miR-17–92 cluster (i.e., miR-17, miR-18a, 
miR-19a/b, miR-20a, and miR-92), especially miR-20a is 
involved in development of OS and metastasis formation 
[148].
Increased level of MiR-93 seems too contributed to 
OS progression and invasion [153]. Over-expression of 
miR-93, miR-181c, and miR-27a, have been previously 
reported in OS [153, 154]. MiR-23a–27a–24-2 cluster 
has been found to be involved in retaining the osteocyte 
phenotype and progression [155]. Increased miR-27a 
was capable of promoting invasion, and proliferation in 
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metastatic sites, leading to the enhancement of osteoblast 
differentiation. Additionally, targeting of peroxisome 
proliferator-activated receptor gamma (PPARγ) through 
miR-27 has been considered to be a second function for 
maintaining osteoblast phenotype during differentiation 
process [155].
Decreased expression of miR-183 was reported to be 
associated with lung metastases and local recurrence of 
OS. In addition, tumor suppressive role of MiR-183 was 
found to be implicated in the inhibition of Ezrin expres-
sion and suppression of MAPK/ERK activation, there-
fore, miR-183-Ezrin-MAPK/ERK axis was suggested to 
prevent progression and metastasis in OS [156]. Accord-
ingly, a study indicated that miR-183 was capable of 
suppressing cell migration and invasion and metastasis 
thought down-regulation of the Ezrin expression [157].
Another study revealed that dysregulation of miR-182 
and miR-183 may play a crucial role in the development 
of OS [158]. The small molecule inhibitors NSC305787 
and NSC668394 have been capable of inhibiting Ezrin 
and preventing OS metastasis. Additionally, ezrin silenc-
ing was suggested to modulate the expression of PI-
PLC in the human OS, and consequently can serve as 
the basis for the prevention of OS progression [159, 
160]. Decreased expression level of miR-183 has been 
demonstrated to be negatively linked to Ezrin mRNA 
over-expression in OS, thus this event was found to 
be associated with clinicopathological characteristics 
including advanced grade, metastasis, recurrence, chem-
oresistance, and poor overall survival, suggesting that it 
might be a novel potential biomarker for predicting prog-
nosis and aggressiveness of OS [161].
Decreased expression of miR-143 has been demon-
strated to be linked to the lung metastasis of OS cells via 
enhancing invasion by matrix metalloproteases-13 over-
expression as a downstream mediator of miR-143, indi-
cating that it might be a novel target for OS metastasis.
Down-regulation of ROCK1-related miRNAs (i.e., 
miR-129-5p, miR-198, miR-144, and miR-145, miR-150, 
miR-202-5p, miR-340, miR-335) has been reported to 
be linked to OS progression and metastasis via targeting 
ROCK1 [162–169]. Thus, OCK1 can be suggested as a 
novel therapeutic target in patients suffering from OS.
A study also demonstrated that over-expression of 
miR-20b contribute to the suppression of the invasion 
and growth of OS cells, and inhibition of the HIF-1α 
and VEGF pathway proteins, whereas the suppression 
of miR-20b was capable of showing the reverse findings. 
In addition, miR-20b showed inhibition of the tumor cell 
process by suppressing HIF-1α level [170].
A deep RNA sequencing indicated that miR-612, miR-
1197, miR-193b-3p, miR-1262, miR-144-3p, and miR-
1269a may contribute to OS metastasis, where further 
development needs an in-depth understanding of mecha-
nisms and targets involved in OS metastasis via regula-
tion of these miRNAs [171].
Activator protein-1 transcription factor, (c-FOS) has 
been suggested as an oncogene in OS and its up-regu-
lation was found to be able to induce OS formation via 
cooperating with c-jun in transgenic mice [172, 173]. Up-
regulation of both c-myc and c-FOS have been reported 
in relapsed OS, which could contribute to the develop-
ment of OS and metastasis [172],therefore, it can be 
concluded that the synchronous increase of c-myc and 
c-FOS might be a novel potential predictor for metastasis 
in primary OS.
Increased expression of c-FOS has been found to 
reverse the suppressive role of miR-101 over-expression 
on proliferation and invasion of OS cells by targeting of 
c-FOS. Therefore, c-FOS can be served as novel thera-
peutic targets for OS.
14Q32‑associated miRNAs cluster in OS
Based on the evidence presented in the literature, 
decreases in the network of 14q32 miRNAs (miR-382, 
miR-369-3p, miR-544, and miR-134) is capable of both 
mediating the regulation of cMYC transcript by increas-
ing cMYC protein and elevating the level of miR-17-92 
clusters [174]. Up-regulation of miR-17-92 has been 
attributed to the aberrant cell division and evading apop-
tosis [175], while lowering the level of cMYC is linked to 
apoptosis in OS cell. 14q32 miRNAs have been reported 
to be involved in suppression of tumor development and 
their expressions may be negatively associated with the 
mitotic potential of osteoblasts. In addition, deregulation 
of 14q32 miRNA cluster may play a key role in osteosar-
coma genesis [176].
An increasing body of evidence suggests that 14q32 
miRNA-cMYC-miR-17–92 miRNA network can be 
involved in the pathogenesis of OS [174]. Another study 
indicated that single nucleotide polymorphism (SNP) 
at the 14q32 miRNA cluster (rs12894467, rs58834075, 
rs12879262, and rs61992671) could contribute to the OS 
susceptibility in the Spanish population [176, 177].
Further development will need new large-scale stud-
ies, functional analyzses and in-depth understanding of 
the molecular mechanisms that underlie regulation and 
mutation of the 14q32 miRNA cluster in OS.
Bioinformatics Analysis of MiRNAs in OS
In this review, OS-associated miRNAs including 
oncomiRNAs and circulating tumor suppressor miR-
NAs were retrieved from the literature. Then, experi-
mentally validated miRNA-target was obtained from 
the miRTarBase web server in at least two experimen-
tal methods. Moreover, the interaction network of all 
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OS-associated miRNAs and their targets was recon-
structed using Cytoscape v.3.6.1.
In addition, the topology of the network was ana-
lyzed based on degree metrics in order to find the most 
important nodes. According to the findings, 5 nodes 
with large degrees in our large network (i.e., > 9; green 
nodes) including B cell lymphoma 2 protein (BCL2), 
vascular endothelial growth factor A (VEGFA), CCND1 
(Cyclin D1), phosphatase and tensin homolog (PTEN) 
and MET were identified as potential hub nodes, (Addi-
tional file 1 and Fig. 2).
BCL2
BCL2 as key antiapoptosis regulator causes not only 
inhibition of cell apoptosis via removal of pro-apoptotic 
genes, but also could play a role in increasing anti-apop-
totic genes and cell viability [178]. It is noteworthy that 
the weak expression of miR-449a in OS was linked to high 
tumor stage and poor prognosis. MiR-449a is capable 
of inducing apoptosis via inhibition of BCL2 expression 
[179]. Furthermore, reduction of miR-143 expression was 
observed in OS, and its inhibitory role in the develop-
ment of OS was regulated through the inhibiting Bcl-2, 
leading to induction of apoptosis [180]. MiR-34a has been 
reported as an important mechanism of lead-inhibited 
Fig. 2 the sub‑network showed the potential hub gene nodes (nodes with over 9 in degrees): BCL2 (13), VEGFA (12), CCND1 (11), PTEN (11), MET 
(10) and miRNAs that regulated them
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tumor invasion and metastasis in OS and its inhibitory 
role may be partially associated with decreased C-IAP2 
and Bcl-2 expression [181]. BCL-2 and its family mem-
bers have been observed to be involved in many types of 
cancer. Therefore, it might be an important target for the 
development of the therapeutic approach in the future.
VEGFA
VEGFA gene is defined to play a crucial role in cellular 
proliferation, survival, and angiogenesis in OS [5, 182]. 
VEGFA was introduced as a poor prognostic marker for 
tumor-free survival in OS, suggesting its potential for 
anti-VEGF therapy [183]. VEGFA expression was found 
to be increased in the OS cell line (SAOS-2) and tissues. 
It has been also revealed that down-regulation of miR-
497 could promote OS cells growth and cisplatin resist-
ance by PI3K/Akt signaling via direct targeting VEGFA, 
while its over-expression was linked to a reverse event. 
MiR-497 has been reported to be capable of modulat-
ing proliferation and apoptosis via targeting VEGFA/
PI3KAKT pathway in OS [184]. MiR-134 has been found 
to be dramatically involved in the inhibition of AKT acti-
vation and proliferation of cell nuclear antigen expression 
in OS. As a result, miR-134 was introduced as a tumor 
suppressor via attenuating VEGFA/VEGFR1 signaling to 
decrease OS progression and angiogenesis [185]. Ample 
evidence indicates that VEGFA/VEGFR1 signaling may 
be a therapeutic target for many kinds of cancer, such as 
OS when previous studies revealed its prognostic role on 
OS [186, 187].
CCND1
CCND1 participates in the regulation of cell cycle pro-
gression [188]. Accumulating evidence suggests that 
CCND1 was over-expressed in human cancers such 
as OS that exerts an oncogenic role in the progression 
of OS via regulating cell proliferation, the cell growth, 
migration, invasion, and metastasis in  vitro and in  vivo 
[189–191]. In addition, over-expression of CCND1 
was found to be linked to shorter overall survival in OS 
patients [190]. A study indicated that miR-195 expression 
could act as a tumor metastasis suppressor via attenuat-
ing CCND1 [190]. MiR-466 is not only responsible for 
inhibition of OS proliferation and cell cycle, but also 
play an important role in promoting apoptosis, leading 
to inhibition of OS progression via targeting CCND1 
[192]. Regarding the importance of CCND1, targeting of 
CCND1 may be useful to develop a therapeutic target for 
preventing the rapid progression and metastasis in indi-
viduals suffering from OS.
PTEN
PTEN is a tumor suppressor gene that plays a key role 
in tumor cell growth, migration, and invasion, as well as 
apoptosis and serves as a key regulator in many types of 
cancer [193, 194]. It has been indicated that miRNA-21, 
PI3K, and AKT are highly expressed in the OS cell line. 
Over-expression of miRNA-21 not only promotes prolif-
eration, but is also linked to overexpression of PI3K/AKT 
signaling pathway proteins via attenuating the expression 
of PTEN, suggesting that PTEN might serve as a target 
of miR‐21 [195]. Additionally, miRNA-21 knockdown 
was capable of suppressing OS cell proliferation by pro-
moting PTEN and TGF-β1 pathway [79, 196]. In OS 
cells, miRNA-300 could be importantly involved in the 
regulation of the Ubiquitination of PTEN via the CRL-
4BDCAF13 E3 ligase [197].The miR-524 expression is 
involved, not only in increased cell proliferation, but also 
in the attenuating apoptosis via activation of the PI3K/
AKT signaling pathway by suppressing PTEN [198]. 
Based on the data presented herein, PTEN can be consid-
ered as a therapeutic target for OS.
Met
Different receptor tyrosine kinases (RTKs) and their 
ligands were highly expressed in OS, e.g., c-Met or 
tyrosine-protein kinase, EGFR, PDGFR, VEGFR, ErbB2, 
IGF-1R, NGFR [199–203]. A study reported that miR-1 
and miR-133b were weakly expressed in OS cell lines, 
that their ectopic expression could cause suppression of 
cell proliferation and invasiveness via attenuating Met 
expression, thus supporting the important role of miR-1 
and miR-133b in OS via Met modulation [204]. Further-
more, miR-133b was observed to be capable of attenuat-
ing the expression level of its targets (i.e., Met, BCL2L2, 
IGF1R, and MCL-1) and may serve as a tumor suppres-
sor in OS [141]. MiR-199a-3p has been demonstrated to 
attenuate some oncogenes and antiapoptotic genes (i.e., 
MET, mTOR, MCL-1 and Bcl-XL, Stat3), suggesting its 
potential tumor suppressive role [205].
Additional file 1 and Fig. 2 depict eclipse (circle); target 
mRNA; octagon node; triangle.
node; rectangle node; miRNAs). In addition, green 
nodes show miRNA target genes that were mapped based 
on the size, color density, and label font size (Minimum:1 
Maximum:13). Additionally, edge color is indicative of 
the source of data as blue and red colors that depicts lit-
erature data and miRTarBase, respectively. Moreover, 
the cluster analysis of the network was performed using 
ClusterOne plugin that resulted in a significant cluster 
with three nodes (p-value: 0.0296732) including hsa-
miR-124, SPHK1, and B7-H3.
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Strategies for microRNA‑based therapy in OS
Ample evidence has also attributed an important role to 
miRNAs in the development of OS by regulating prolifer-
ation, metastasis, invasion, apoptosis, and angiogenesis. 
Based on the available data, aberrant expression levels 
of miRNAs have been documented in OS. Several miR-
NAs have been confirmed as cancer biomarkers by the 
US Federal Drug Administration (FDA) in clinical trials. 
A large number of studies are underway to assess circu-
lating miRNAs for providing novel diagnostic and prog-
nostic markers, as well as therapeutic targets that will 
be valuable and non-invasive for patients suffering from 
cancer [206–208].
Regarding the field of liquid biopsy, there are still tech-
nical challenges for detecting circulating miRNAs includ-
ing sample handling, and isolation and normalization of 
miRNAs, i.e., techniques of exosome isolation and purifi-
cation of RNA, normalization of an exogenous reference 
RNA for decreasing variation associated with RNA deg-
radation [208].
Further development will need an in-depth under-
standing of the target molecules of miRNAs and molec-
ular interference in OS that underlie its influence in 
order to develop therapeutic strategies because miRNAs 
replacement therapy can be a valuable strategy in cancer 
treatment and draw interest from studies. To the best 
of our knowledge, all registered clinical trials at clini-
caltrials.gov are approximately based on the detection 
of miRNAs expression in many kinds of disease such as 
cancer [209, 210], where there were limitations and chal-
lenges for miRNA delivery into cancer in clinical trials 
(Fig. 3). Currently, two miRNA‐based strategies including 
miRNA mimics (e.g., restoration, replacement, or over-
expression of miRNAs) and antagomiRs (e.g., miRNA 
down-regulation and inhibition) are considered in regard 
to functions of miRNAs for developing miRNA-based 
therapy [210, 211].
MicroRNA mimics and antagonists
MiRNA mimics are applied as an innovative approach 
for restoring the activity of tumor suppressive miRNAs 
via replacing down-regulated miRNA by applying chemi-
cally designed (2′-O′methoxy) double-stranded RNA-
like molecules. MiRNA mimics can be used via loading 
into RNA-induced silencing complex (RISC), which is 
specifically capable of downstream inhibiting of the tar-
get mRNAs. It is worth noting that miRNA mimics not 
only directly restore loss of tumor suppressor miRNA in 
cancer cells, but also can shed light on the therapeutic 
approach with normal expression levels of miRNA [212, 
213]. MiRNA mimics as a new avenue will be greatly ben-
eficial by the administration of miRNA-mimetic agents 
that their potential therapeutic effects can be truly evalu-
ated for cancer management in clinical trials. However, 
challenges in the field of miRNA-mimetic agent delivery 
remind, where various approaches have recently been 
investigated for delivery agents and their delivery will be 
greatly favorable in achieving affordable, safe, and effi-
cient delivery.
There is interest in developing miRNA-targeting 
therapies, where miRNA inhibitors and oligomers are 
developed for inhibiting miRNA biogenesis, including 
anti‐miRNA oligonucleotides (AMO), locked‐nucleic‐
acid antisense oligonucleotides (LNAs), miRNA masks, 
antagomirs, miRNA sponges, nanoparticles (NPs), multi-
target anti-microRNA antisense oligonucleotide (MTg-
AMOs) [214–217].
AMOs (i.e., single-stranded, DNA-like molecules 
with chemical modification, antisense oligonucleotides 
(ASOs) have been developed not only for inhibiting 
miRNA function to specific signaling pathways, but also 
for blocking the function of malignancy-related miRNA. 
They are capable of providing antisense oligonucleotides 
(ASOs)–miRNA duplex by watson–crick binding, result-
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MiRNA antagonists-AMO along with complementary 
sequences are developed to be complementary to a tar-
geted miRNA gene, where are specifically able to block 
miRNA function and RISC assembly, leading to over-
expression of tumor suppressor genes [213, 218]. It is 
noteworthy that targeted miRNA can be considered as 
a master predictor of response to miRNA antagonist 
therapy for certain tumors [213]. Providing chemically 
modified miRNA mimics with an oligonucleotide render 
a considerable challenge and the different proprietary 
modification approaches are suggested in chemically 
modified off-the-shelf miRNA mimics [219].
Nevertheless, the configuration of miRNAs is impos-
sible to be processed using RISC [220]. Regarding the 
miRNA‐reduction therapy, a single miRNA is not appro-
priately sufficient for clinical therapy because of the pres-
ence of different oncomirs and targets. Another challenge 
of miRNA‐reduction therapy is described to be the deg-
radation of oligonucleotides via endonucleases in the 
blood [217, 221]. Current evidence suggests an impor-
tant role for importing exogenous miRNAs in miRNA 
replacement therapy via inhibition of proliferation or 
induction of apoptosis in tumor cells [217, 222].
LNAs are defined as modified RNA nucleotides, that 
belong to a class of antisense ON’s; current evidence has 
also attributed a role to the methylene bridge in LNAs 
in conformational locking of the ribosome and shows 
remarkable binding affinity to a single-stranded RNA 
[223]. LNAs have attracted the interest of researchers for 
developing therapeutic strategies in cancer. These mol-
ecules are capable of increasing target affinity and are sta-
bilized to elevate stability against nuclease degradation. 
Suppression of oncomirs has been described as a strategy 
using LNAs, synthetic anti-miRNAs, antagonists, and TS 
miRNAs, as well as ASOs [224, 225].
Another approach is described to block the function of 
a miRNA of interest by applying a miRNA sponge. The 
miRNA sponge with several complementary 3′ UTR 
mRNA sites for targeted miRNA is capable of induc-
ing continuous loss-of-function phenotypes for targeted 
miRNA in cell culture and transgenic organisms, as well 
as virally infected cells [211, 226]. Many miRNA sponge 
types have been previously constructed as target mimics 
such as miRT sequences decoys, and lentivirus-mediated 
antagomir (miRNA erasers) [227–230].
MiRNA sponges can be potentially applied for target-
ing the family of miRNAs, as compared to antisense oli-
gonucleotides which are able to target a single miRNA 
[226]. However, there are some challenges herein; it 
should be taken into consideration that the use of sponge 
methods can show different levels of inhibition in many 
contexts. Furthermore, there are less free miRNAs, 
when cells exhibit a large pool of endogenous targets for 
targeted miRNA family; therefore, it can be concluded 
that a lower dose of sponge RNA can be sufficiently 
effective for blocking a miRNA of interest. Nevertheless, 
determining the effectiveness of sponge (efficacy) is cur-
rently considered to be challenging as compared to the 
validation of successful miRNA deletion. The validation 
of efficacy for sponge method is available using methods 
such as cell culture [231]. On the other hand, therapeutic 
applications of miRNAs need a favorable invivo delivery 
device or mechanism [232], where delivery is considered 
as one of the major challenges.
Conclusion
Currently, ample evidence suggests that miRNAs are 
key regulators of tumor initiation, development, dis-
semination and the inhibition of proliferation or induc-
tion of apoptosis in tumor cells, in parallel, targeting of 
miRNAs should be also being considered for therapeu-
tic strategies, which are related to suppression of tumor 
growth and metastasis in OS.
Our bioinformatics analysis revealed that BCL2 
(antiapoptosis regulator), VEGFA (cellular prolifera-
tion, survival, and angiogenesis), CCND (oncogenic 
properties: cell proliferation, the cell growth, migration, 
invasion, and metastasis), PTEN (tumor suppressor 
gene) and MET (oncogenic properties) were potential 
hub gene nodes in the subnetwork of OS. MiR-449a 
and MiR-34a are considered to be involved in the apop-
tosis pathway and suppression of OS, respectively, via 
regulating BCL2.
Overexpression of miR-497 and miR-134 may be 
involved in suppression of OS progression via target-
ing VEGFA and VEGFA/VEGFR1, respectively. In addi-
tion, miR-195 and miR-466 expressions could act as a 
tumor metastasis suppressor and OS progression inhibi-
tor, respectively, via targeting oncogenic CCND1. Fur-
thermore, miR-524 and miRNA-21 knockdown may be 
capable of inhibiting OS cell proliferation by promoting 
PTEN. Additionally, miR-1, miR-133b and MiR-199a-3p 
may be considered key tumor suppressors in OS through 
inhibition of cell proliferation and invasiveness via atten-
uating Met expression.
Further studies are required to fully understand the 
biological functions of miRNAs derived from serum/
plasma, tissues, and other biological fluids, as valuable 
regulators and promising markers are implicated in the 
development of OS. Although there are lots of chal-
lenges for normalization of miRNA, miRNAs may be 
valuable biomarkers for determining risk of OS progres-
sion. Underlying functions and biological mechanisms 
of various miRNAs are currently far from favorably 
understood. At present, there are two key miRNA‐based 
Page 15 of 20Otoukesh et al. Cancer Cell Int          (2020) 20:254  
strategies including miRNA mimics and antagomiRs to 
develop miRNA-based therapy for modulating tumor 
microenvironment and inhibiting tumor development.
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